Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 1996

View Archived Issues

Teva's generic minoxidil approved in U.S.

Cefdinir close to filing in U.S.

DepoAmikacin phase I trial completed

Abelcet trial results in children favorable

Bayer claims anti-HIV quinolone carboxylic acids

VP-63843 effective in phase II

Sankyo claims HIV protease inhibitors

HIV protease inhibitors described by Hoechst Marion Roussel

Ciba-Geigy selects CGP-61755 for development

Canada, Brazil approve Invirase for marketing

Didanosine + hydroxyurea effective in reducing HIV viral load

BufferGel development assisted by NIH

GEM-91 + AZT enters clinical trials in Europe

Ryan develops improved formulation of CoQ10

Androgel-DHT in phase II for AIDS indications

TNF-bp in clinical testing

CellCept available in Europe

Terramed receives patent protection for vaccine technology

CB-30865 selected for further study

Onconase development update

Estrasine presented at NCI-EORTC

Alnorin reported in phase I

PD-154309 revealed at 211th ACS

AntiCancer, Celltech present gelatinase A inhibitor at NCI-EORTC

Agouron continues to discover MMP inhibitors

Taisho claims antitumor steroids

Japanese scientists present antitumor agents

Peptech neuropeptide antagonists in clinical studies

ONYX-015 enters clinical testing

Dipyridamole analogue more potent than parent drug

Cancer Research Center, Moscow, presents MDR inhibitors at NCI-EORTC

NU-1064 and NU-1076, PARP inhibitors

Photofrin approved for marketing in France

Fujisawa describes cathepsin L/B inhibitor of fungal origin

Cortecs' oral salmon calcitonin shows favorable phase II results

Human Genome Sciences' research into cathepsin K

ACAT inhibitor reported by Nisshin Flour Milling

Warner-Lambert, Pfizer intend to copromote atorvastatin

FDA approves new indication for Pravachol

Warner-Lambert reports NPY1 antagonist

Obesity gene identified

RF-1051 cleared to enter phase II

Sero-Strip HIV-1/2 shows 100% efficacy in Swedish study

BASF reports dopamine D3 ligands

P&U's U-99363E shows high affinity for D4 receptors

New dopamine D3 ligand from Warner-Lambert

Oncogene Sciences acquires MYCOsearch

Signal, Tanabe Seiyaku to collaborate on drug discovery

GS-2888, permeation enhancer reported by Gilead, Glaxo Wellcome

Targeted Genetics and RGene to merge

GP-3269, new AK inhibitor from Gensia

Cerebyx approvable in USA

Myotrophin NDA submission on track

Dolasetron submitted for approval in U.S.

Lilly reports cannabinoid receptor antagonists

New Takeda compounds suppress increased vascular permeability

SKB reports calcium antagonists for stroke

Combined thrombolytic/neuroprotective agents more effective in treating stroke

Nerve growth synthesis inducers produce neuroprotective effects

Leukotriene D4 antagonists reported by Leo Denmark

Two novel series of LTB4 antagonists from Boehringer Ingelheim

Abbott claims new 5-LO inhibitors

CMI-568, dual PAF antagonist and 5-LO inhibitor from CytoMed

Nikken Chemicals describes antiallergy agents

SKB discloses NK3 antagonists in patent literature

CP-191166, angiotensin II antagonist from Pfizer

Zanidip approved for marketing in U.K.

EMD-94246, promising endothelin antagonist for hypertension

New ETA antagonist from SmithKline Beecham: SB-225757

Posicor submitted for approval

Corvert now available in U.S.

Yamanouchi selects YM-471 for clinical development

New series of thrombin inhibitors claimed by Thomae

SD-998, thrombin inhibitor

First clinical results for CVS-1123

Corvas presents preclinical data for NAPc2

Antiplatelet agents emerging from the Thomae pipeline

More antiplatelet agents from Thomae

XQ-870, fibrinogen antagonist presented by DuPont Merck

SNAP-5399 presented at 211th ACS

FDA gives green light to Milkhaus for HP-4 clinical trial

Byk Gulden researches anti-Helicobacter agents

FDA approves Prilosec + Biaxin combination for H. pylori

Taisho reports 5-HT4 agonists for GI disorders

YM-47813 revealed at 211th ACS

Troglitazone NDA filing expected soon

FDA designates orphan drug for Peyronie's disease

FemPatch approval imminent in USA

Glaxo Wellcome/BioChem Pharma antitumor agent described at 211th ACS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...